Compare Ishares Msci Italy ETF (EWI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Sanofi SA — how do they compare? Ishares Msci Italy ETF trades at $63.19, while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| EWI | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $52.34 |
52-Week Low | $50.31 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI trades at $63.165, showing minimal daily movement with a slight decline of 0.01%. The technical outlook is bullish based on moving averages, though oscillators signal neutrality with RSI readings above 80 indicating potential overbought conditions. Recent news highlights Italy's market strength with EWI hitting a 52-week high in June 2026, driven by improving industrial data and recovery narrative. A dividend of $1.17 is scheduled for June 2026, providing income appeal.
The stock benefits from positive European market sentiment and Italy's economic recovery, but faces risks from ECB rate policy and energy price volatility. Technical indicators suggest near-term consolidation may be needed given overbought signals. Long-term prospects appear favorable if Italy's economic momentum continues, though investors should monitor ECB decisions and energy market developments closely.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
